nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—epilepsy syndrome	0.253	0.706	CbGaD
Afatinib—ABCB1—epilepsy syndrome	0.105	0.294	CbGaD
Afatinib—ABCB1—Levetiracetam—epilepsy syndrome	0.0348	0.208	CbGbCtD
Afatinib—ABCB1—Clobazam—epilepsy syndrome	0.0241	0.145	CbGbCtD
Afatinib—ABCB1—Lamotrigine—epilepsy syndrome	0.0232	0.139	CbGbCtD
Afatinib—ABCB1—Carbamazepine—epilepsy syndrome	0.02	0.12	CbGbCtD
Afatinib—ABCB1—Phenytoin—epilepsy syndrome	0.0179	0.107	CbGbCtD
Afatinib—ABCB1—Phenobarbital—epilepsy syndrome	0.016	0.0957	CbGbCtD
Afatinib—ABCB1—Midazolam—epilepsy syndrome	0.0157	0.0944	CbGbCtD
Afatinib—ABCB1—Diazepam—epilepsy syndrome	0.0151	0.0907	CbGbCtD
Afatinib—PHKG2—hindbrain—epilepsy syndrome	0.00399	0.0562	CbGeAlD
Afatinib—DYRK1A—hindbrain—epilepsy syndrome	0.00345	0.0487	CbGeAlD
Afatinib—PHKG2—brainstem—epilepsy syndrome	0.00229	0.0322	CbGeAlD
Afatinib—ERBB2—Bortezomib—Lacosamide—epilepsy syndrome	0.00206	1	CbGdCrCtD
Afatinib—ERBB4—brainstem—epilepsy syndrome	0.00205	0.029	CbGeAlD
Afatinib—ERBB4—forebrain—epilepsy syndrome	0.00198	0.028	CbGeAlD
Afatinib—DYRK1A—brainstem—epilepsy syndrome	0.00198	0.0279	CbGeAlD
Afatinib—DYRK1A—forebrain—epilepsy syndrome	0.00191	0.0269	CbGeAlD
Afatinib—ERBB4—telencephalon—epilepsy syndrome	0.00182	0.0257	CbGeAlD
Afatinib—DYRK1A—telencephalon—epilepsy syndrome	0.00176	0.0247	CbGeAlD
Afatinib—Vandetanib—TYRO3—epilepsy syndrome	0.00165	0.227	CrCbGaD
Afatinib—PHKG2—medulla oblongata—epilepsy syndrome	0.00159	0.0225	CbGeAlD
Afatinib—EGFR—telencephalon—epilepsy syndrome	0.00155	0.0218	CbGeAlD
Afatinib—ABL1—hindbrain—epilepsy syndrome	0.0015	0.0212	CbGeAlD
Afatinib—ERBB4—medulla oblongata—epilepsy syndrome	0.00143	0.0202	CbGeAlD
Afatinib—IRAK1—telencephalon—epilepsy syndrome	0.00136	0.0192	CbGeAlD
Afatinib—EPHA6—head—epilepsy syndrome	0.00131	0.0185	CbGeAlD
Afatinib—ERBB4—midbrain—epilepsy syndrome	0.00131	0.0185	CbGeAlD
Afatinib—ERBB4—spinal cord—epilepsy syndrome	0.00128	0.018	CbGeAlD
Afatinib—PHKG2—head—epilepsy syndrome	0.00126	0.0178	CbGeAlD
Afatinib—Vandetanib—FYN—epilepsy syndrome	0.00125	0.172	CrCbGaD
Afatinib—EPHA6—nervous system—epilepsy syndrome	0.00124	0.0175	CbGeAlD
Afatinib—HIPK4—brain—epilepsy syndrome	0.0012	0.0169	CbGeAlD
Afatinib—PHKG2—nervous system—epilepsy syndrome	0.0012	0.0169	CbGeAlD
Afatinib—EPHA6—central nervous system—epilepsy syndrome	0.0012	0.0169	CbGeAlD
Afatinib—PHKG2—central nervous system—epilepsy syndrome	0.00115	0.0163	CbGeAlD
Afatinib—ERBB2—head—epilepsy syndrome	0.00114	0.016	CbGeAlD
Afatinib—ERBB4—head—epilepsy syndrome	0.00114	0.016	CbGeAlD
Afatinib—PHKG2—cerebellum—epilepsy syndrome	0.00113	0.0159	CbGeAlD
Afatinib—DYRK1A—head—epilepsy syndrome	0.00109	0.0154	CbGeAlD
Afatinib—ERBB4—nervous system—epilepsy syndrome	0.00108	0.0152	CbGeAlD
Afatinib—ERBB2—nervous system—epilepsy syndrome	0.00108	0.0152	CbGeAlD
Afatinib—ERBB4—central nervous system—epilepsy syndrome	0.00104	0.0146	CbGeAlD
Afatinib—ERBB2—central nervous system—epilepsy syndrome	0.00104	0.0146	CbGeAlD
Afatinib—DYRK1A—nervous system—epilepsy syndrome	0.00104	0.0146	CbGeAlD
Afatinib—ERBB2—cerebellum—epilepsy syndrome	0.00101	0.0143	CbGeAlD
Afatinib—ERBB4—cerebellum—epilepsy syndrome	0.00101	0.0143	CbGeAlD
Afatinib—DYRK1A—central nervous system—epilepsy syndrome	0.000998	0.0141	CbGeAlD
Afatinib—IRAK1—midbrain—epilepsy syndrome	0.000979	0.0138	CbGeAlD
Afatinib—DYRK1A—cerebellum—epilepsy syndrome	0.000975	0.0137	CbGeAlD
Afatinib—Vandetanib—TEK—epilepsy syndrome	0.000974	0.134	CrCbGaD
Afatinib—EPHA6—brain—epilepsy syndrome	0.000949	0.0134	CbGeAlD
Afatinib—PHKG2—brain—epilepsy syndrome	0.000915	0.0129	CbGeAlD
Afatinib—Vandetanib—RET—epilepsy syndrome	0.000905	0.124	CrCbGaD
Afatinib—ABL1—brainstem—epilepsy syndrome	0.000861	0.0121	CbGeAlD
Afatinib—EGFR—cerebellum—epilepsy syndrome	0.000859	0.0121	CbGeAlD
Afatinib—ERBB2—brain—epilepsy syndrome	0.000823	0.0116	CbGeAlD
Afatinib—ERBB4—brain—epilepsy syndrome	0.000823	0.0116	CbGeAlD
Afatinib—DYRK1A—brain—epilepsy syndrome	0.000792	0.0112	CbGeAlD
Afatinib—ABL1—telencephalon—epilepsy syndrome	0.000764	0.0108	CbGeAlD
Afatinib—IRAK1—cerebellum—epilepsy syndrome	0.000758	0.0107	CbGeAlD
Afatinib—EGFR—brain—epilepsy syndrome	0.000698	0.00984	CbGeAlD
Afatinib—IRAK1—brain—epilepsy syndrome	0.000615	0.00868	CbGeAlD
Afatinib—ABL1—medulla oblongata—epilepsy syndrome	0.0006	0.00846	CbGeAlD
Afatinib—ABL1—midbrain—epilepsy syndrome	0.000549	0.00774	CbGeAlD
Afatinib—ABL1—spinal cord—epilepsy syndrome	0.000535	0.00755	CbGeAlD
Afatinib—Vandetanib—SRC—epilepsy syndrome	0.000506	0.0695	CrCbGaD
Afatinib—ABCG2—telencephalon—epilepsy syndrome	0.000482	0.00679	CbGeAlD
Afatinib—ABL1—head—epilepsy syndrome	0.000476	0.00671	CbGeAlD
Afatinib—Vandetanib—KDR—epilepsy syndrome	0.000476	0.0653	CrCbGaD
Afatinib—ABL1—nervous system—epilepsy syndrome	0.000451	0.00636	CbGeAlD
Afatinib—ABL1—central nervous system—epilepsy syndrome	0.000434	0.00612	CbGeAlD
Afatinib—ABL1—cerebellum—epilepsy syndrome	0.000424	0.00598	CbGeAlD
Afatinib—Vandetanib—VEGFA—epilepsy syndrome	0.000403	0.0553	CrCbGaD
Afatinib—ABCG2—medulla oblongata—epilepsy syndrome	0.000379	0.00534	CbGeAlD
Afatinib—ABCG2—midbrain—epilepsy syndrome	0.000346	0.00488	CbGeAlD
Afatinib—ABL1—brain—epilepsy syndrome	0.000345	0.00486	CbGeAlD
Afatinib—ABCG2—spinal cord—epilepsy syndrome	0.000338	0.00476	CbGeAlD
Afatinib—ABCG2—cerebellum—epilepsy syndrome	0.000268	0.00377	CbGeAlD
Afatinib—ABCB1—forebrain—epilepsy syndrome	0.000258	0.00364	CbGeAlD
Afatinib—Vandetanib—ABCG2—epilepsy syndrome	0.000249	0.0341	CrCbGaD
Afatinib—ABCB1—telencephalon—epilepsy syndrome	0.000238	0.00335	CbGeAlD
Afatinib—Gefitinib—ABCG2—epilepsy syndrome	0.000236	0.0324	CrCbGaD
Afatinib—ABCG2—brain—epilepsy syndrome	0.000217	0.00307	CbGeAlD
Afatinib—ABCB1—medulla oblongata—epilepsy syndrome	0.000187	0.00263	CbGeAlD
Afatinib—Gefitinib—CYP2C19—epilepsy syndrome	0.000186	0.0255	CrCbGaD
Afatinib—ABCB1—midbrain—epilepsy syndrome	0.000171	0.00241	CbGeAlD
Afatinib—ABCB1—spinal cord—epilepsy syndrome	0.000166	0.00235	CbGeAlD
Afatinib—Upper respiratory tract infection—Topiramate—epilepsy syndrome	0.000165	0.000812	CcSEcCtD
Afatinib—Insomnia—Lamotrigine—epilepsy syndrome	0.000164	0.00081	CcSEcCtD
Afatinib—Headache—Acetazolamide—epilepsy syndrome	0.000164	0.000807	CcSEcCtD
Afatinib—Decreased appetite—Carbamazepine—epilepsy syndrome	0.000163	0.000806	CcSEcCtD
Afatinib—Body temperature increased—Zonisamide—epilepsy syndrome	0.000163	0.000802	CcSEcCtD
Afatinib—Asthenia—Fosphenytoin—epilepsy syndrome	0.000162	0.000801	CcSEcCtD
Afatinib—Alopecia—Pregabalin—epilepsy syndrome	0.000162	0.000801	CcSEcCtD
Afatinib—Gastrointestinal disorder—Carbamazepine—epilepsy syndrome	0.000162	0.0008	CcSEcCtD
Afatinib—Fatigue—Carbamazepine—epilepsy syndrome	0.000162	0.000799	CcSEcCtD
Afatinib—Dyspnoea—Lamotrigine—epilepsy syndrome	0.000162	0.000799	CcSEcCtD
Afatinib—Mental disorder—Pregabalin—epilepsy syndrome	0.000161	0.000794	CcSEcCtD
Afatinib—Constipation—Carbamazepine—epilepsy syndrome	0.000161	0.000793	CcSEcCtD
Afatinib—Dizziness—Propofol—epilepsy syndrome	0.00016	0.000791	CcSEcCtD
Afatinib—Diarrhoea—Levetiracetam—epilepsy syndrome	0.00016	0.000791	CcSEcCtD
Afatinib—Weight decreased—Topiramate—epilepsy syndrome	0.00016	0.00079	CcSEcCtD
Afatinib—Pruritus—Fosphenytoin—epilepsy syndrome	0.00016	0.00079	CcSEcCtD
Afatinib—Dyspepsia—Lamotrigine—epilepsy syndrome	0.00016	0.000789	CcSEcCtD
Afatinib—Malnutrition—Pregabalin—epilepsy syndrome	0.00016	0.000789	CcSEcCtD
Afatinib—Pneumonia—Topiramate—epilepsy syndrome	0.000159	0.000783	CcSEcCtD
Afatinib—Asthenia—Vigabatrin—epilepsy syndrome	0.000158	0.00078	CcSEcCtD
Afatinib—Decreased appetite—Lamotrigine—epilepsy syndrome	0.000158	0.000779	CcSEcCtD
Afatinib—Infestation—Topiramate—epilepsy syndrome	0.000158	0.000779	CcSEcCtD
Afatinib—Infestation NOS—Topiramate—epilepsy syndrome	0.000158	0.000779	CcSEcCtD
Afatinib—Eye disorder—Gabapentin—epilepsy syndrome	0.000157	0.000776	CcSEcCtD
Afatinib—Dizziness—Midazolam—epilepsy syndrome	0.000157	0.000774	CcSEcCtD
Afatinib—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	0.000157	0.000774	CcSEcCtD
Afatinib—Body temperature increased—Clonazepam—epilepsy syndrome	0.000157	0.000773	CcSEcCtD
Afatinib—Fatigue—Lamotrigine—epilepsy syndrome	0.000157	0.000773	CcSEcCtD
Afatinib—Dysgeusia—Pregabalin—epilepsy syndrome	0.000157	0.000772	CcSEcCtD
Afatinib—Pruritus—Vigabatrin—epilepsy syndrome	0.000156	0.00077	CcSEcCtD
Afatinib—Asthenia—Diazepam—epilepsy syndrome	0.000156	0.000768	CcSEcCtD
Afatinib—Body temperature increased—Phenytoin—epilepsy syndrome	0.000156	0.000768	CcSEcCtD
Afatinib—Constipation—Lamotrigine—epilepsy syndrome	0.000155	0.000766	CcSEcCtD
Afatinib—Renal failure—Topiramate—epilepsy syndrome	0.000155	0.000765	CcSEcCtD
Afatinib—Nausea—Acetazolamide—epilepsy syndrome	0.000155	0.000765	CcSEcCtD
Afatinib—Dizziness—Levetiracetam—epilepsy syndrome	0.000155	0.000765	CcSEcCtD
Afatinib—Body temperature increased—Oxcarbazepine—epilepsy syndrome	0.000155	0.000764	CcSEcCtD
Afatinib—Diarrhoea—Fosphenytoin—epilepsy syndrome	0.000155	0.000764	CcSEcCtD
Afatinib—Back pain—Pregabalin—epilepsy syndrome	0.000155	0.000763	CcSEcCtD
Afatinib—Cough—Valproic Acid—epilepsy syndrome	0.000154	0.000761	CcSEcCtD
Afatinib—Vomiting—Propofol—epilepsy syndrome	0.000154	0.000761	CcSEcCtD
Afatinib—Stomatitis—Topiramate—epilepsy syndrome	0.000154	0.000759	CcSEcCtD
Afatinib—Muscle spasms—Pregabalin—epilepsy syndrome	0.000154	0.000758	CcSEcCtD
Afatinib—Pruritus—Diazepam—epilepsy syndrome	0.000154	0.000758	CcSEcCtD
Afatinib—Conjunctivitis—Topiramate—epilepsy syndrome	0.000153	0.000757	CcSEcCtD
Afatinib—Urinary tract infection—Topiramate—epilepsy syndrome	0.000153	0.000757	CcSEcCtD
Afatinib—Rash—Propofol—epilepsy syndrome	0.000153	0.000755	CcSEcCtD
Afatinib—Dermatitis—Propofol—epilepsy syndrome	0.000153	0.000754	CcSEcCtD
Afatinib—Headache—Propofol—epilepsy syndrome	0.000152	0.00075	CcSEcCtD
Afatinib—Mediastinal disorder—Gabapentin—epilepsy syndrome	0.000152	0.000749	CcSEcCtD
Afatinib—Vomiting—Midazolam—epilepsy syndrome	0.000151	0.000745	CcSEcCtD
Afatinib—Diarrhoea—Vigabatrin—epilepsy syndrome	0.000151	0.000744	CcSEcCtD
Afatinib—Asthenia—Felbamate—epilepsy syndrome	0.000151	0.000744	CcSEcCtD
Afatinib—Rash—Midazolam—epilepsy syndrome	0.00015	0.000738	CcSEcCtD
Afatinib—Dizziness—Fosphenytoin—epilepsy syndrome	0.00015	0.000738	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	0.00015	0.000738	CcSEcCtD
Afatinib—Dermatitis—Midazolam—epilepsy syndrome	0.00015	0.000738	CcSEcCtD
Afatinib—Vomiting—Levetiracetam—epilepsy syndrome	0.000149	0.000735	CcSEcCtD
Afatinib—Epistaxis—Topiramate—epilepsy syndrome	0.000149	0.000734	CcSEcCtD
Afatinib—Alopecia—Gabapentin—epilepsy syndrome	0.000149	0.000734	CcSEcCtD
Afatinib—Headache—Midazolam—epilepsy syndrome	0.000149	0.000734	CcSEcCtD
Afatinib—Pruritus—Felbamate—epilepsy syndrome	0.000149	0.000733	CcSEcCtD
Afatinib—Body temperature increased—Carbamazepine—epilepsy syndrome	0.000149	0.000733	CcSEcCtD
Afatinib—Diarrhoea—Diazepam—epilepsy syndrome	0.000149	0.000733	CcSEcCtD
Afatinib—ABCB1—head—epilepsy syndrome	0.000148	0.00209	CbGeAlD
Afatinib—Rash—Levetiracetam—epilepsy syndrome	0.000148	0.000729	CcSEcCtD
Afatinib—Dermatitis—Levetiracetam—epilepsy syndrome	0.000148	0.000728	CcSEcCtD
Afatinib—Asthenia—Zonisamide—epilepsy syndrome	0.000148	0.000728	CcSEcCtD
Afatinib—Mental disorder—Gabapentin—epilepsy syndrome	0.000148	0.000728	CcSEcCtD
Afatinib—Headache—Levetiracetam—epilepsy syndrome	0.000147	0.000724	CcSEcCtD
Afatinib—Malnutrition—Gabapentin—epilepsy syndrome	0.000147	0.000723	CcSEcCtD
Afatinib—Dizziness—Vigabatrin—epilepsy syndrome	0.000146	0.000719	CcSEcCtD
Afatinib—Pruritus—Zonisamide—epilepsy syndrome	0.000146	0.000718	CcSEcCtD
Afatinib—Nausea—Propofol—epilepsy syndrome	0.000144	0.000711	CcSEcCtD
Afatinib—Vomiting—Fosphenytoin—epilepsy syndrome	0.000144	0.00071	CcSEcCtD
Afatinib—Diarrhoea—Felbamate—epilepsy syndrome	0.000144	0.000709	CcSEcCtD
Afatinib—Body temperature increased—Lamotrigine—epilepsy syndrome	0.000144	0.000708	CcSEcCtD
Afatinib—Dysgeusia—Gabapentin—epilepsy syndrome	0.000144	0.000708	CcSEcCtD
Afatinib—Dizziness—Diazepam—epilepsy syndrome	0.000144	0.000708	CcSEcCtD
Afatinib—Infection—Valproic Acid—epilepsy syndrome	0.000143	0.000707	CcSEcCtD
Afatinib—Rash—Fosphenytoin—epilepsy syndrome	0.000143	0.000704	CcSEcCtD
Afatinib—Dermatitis—Fosphenytoin—epilepsy syndrome	0.000143	0.000703	CcSEcCtD
Afatinib—Asthenia—Clonazepam—epilepsy syndrome	0.000142	0.000702	CcSEcCtD
Afatinib—Back pain—Gabapentin—epilepsy syndrome	0.000142	0.0007	CcSEcCtD
Afatinib—Headache—Fosphenytoin—epilepsy syndrome	0.000142	0.000699	CcSEcCtD
Afatinib—Nervous system disorder—Valproic Acid—epilepsy syndrome	0.000142	0.000698	CcSEcCtD
Afatinib—Asthenia—Phenytoin—epilepsy syndrome	0.000141	0.000697	CcSEcCtD
Afatinib—Nausea—Midazolam—epilepsy syndrome	0.000141	0.000696	CcSEcCtD
Afatinib—Muscle spasms—Gabapentin—epilepsy syndrome	0.000141	0.000695	CcSEcCtD
Afatinib—Diarrhoea—Zonisamide—epilepsy syndrome	0.000141	0.000694	CcSEcCtD
Afatinib—Asthenia—Oxcarbazepine—epilepsy syndrome	0.000141	0.000693	CcSEcCtD
Afatinib—ABCB1—nervous system—epilepsy syndrome	0.00014	0.00198	CbGeAlD
Afatinib—Pruritus—Clonazepam—epilepsy syndrome	0.00014	0.000692	CcSEcCtD
Afatinib—Vomiting—Vigabatrin—epilepsy syndrome	0.00014	0.000692	CcSEcCtD
Afatinib—Skin disorder—Valproic Acid—epilepsy syndrome	0.00014	0.000692	CcSEcCtD
Afatinib—Urinary tract disorder—Topiramate—epilepsy syndrome	0.00014	0.00069	CcSEcCtD
Afatinib—Cough—Pregabalin—epilepsy syndrome	0.00014	0.000688	CcSEcCtD
Afatinib—Pruritus—Phenytoin—epilepsy syndrome	0.000139	0.000687	CcSEcCtD
Afatinib—Connective tissue disorder—Topiramate—epilepsy syndrome	0.000139	0.000687	CcSEcCtD
Afatinib—Nausea—Levetiracetam—epilepsy syndrome	0.000139	0.000687	CcSEcCtD
Afatinib—Rash—Vigabatrin—epilepsy syndrome	0.000139	0.000686	CcSEcCtD
Afatinib—Dizziness—Felbamate—epilepsy syndrome	0.000139	0.000685	CcSEcCtD
Afatinib—Dermatitis—Vigabatrin—epilepsy syndrome	0.000139	0.000685	CcSEcCtD
Afatinib—Urethral disorder—Topiramate—epilepsy syndrome	0.000139	0.000685	CcSEcCtD
Afatinib—Pruritus—Oxcarbazepine—epilepsy syndrome	0.000139	0.000684	CcSEcCtD
Afatinib—Headache—Vigabatrin—epilepsy syndrome	0.000138	0.000681	CcSEcCtD
Afatinib—Vomiting—Diazepam—epilepsy syndrome	0.000138	0.000681	CcSEcCtD
Afatinib—Gefitinib—CYP2D6—epilepsy syndrome	0.000138	0.0189	CrCbGaD
Afatinib—Rash—Diazepam—epilepsy syndrome	0.000137	0.000675	CcSEcCtD
Afatinib—Dermatitis—Diazepam—epilepsy syndrome	0.000137	0.000675	CcSEcCtD
Afatinib—Dizziness—Zonisamide—epilepsy syndrome	0.000136	0.000671	CcSEcCtD
Afatinib—Headache—Diazepam—epilepsy syndrome	0.000136	0.000671	CcSEcCtD
Afatinib—Diarrhoea—Clonazepam—epilepsy syndrome	0.000136	0.000669	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	0.000135	0.000667	CcSEcCtD
Afatinib—ABCB1—central nervous system—epilepsy syndrome	0.000135	0.0019	CbGeAlD
Afatinib—Asthenia—Carbamazepine—epilepsy syndrome	0.000135	0.000665	CcSEcCtD
Afatinib—Diarrhoea—Phenytoin—epilepsy syndrome	0.000135	0.000665	CcSEcCtD
Afatinib—Nausea—Fosphenytoin—epilepsy syndrome	0.000134	0.000663	CcSEcCtD
Afatinib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	0.000134	0.000661	CcSEcCtD
Afatinib—Vomiting—Felbamate—epilepsy syndrome	0.000134	0.000659	CcSEcCtD
Afatinib—Pruritus—Carbamazepine—epilepsy syndrome	0.000133	0.000656	CcSEcCtD
Afatinib—Rash—Felbamate—epilepsy syndrome	0.000132	0.000654	CcSEcCtD
Afatinib—Eye disorder—Topiramate—epilepsy syndrome	0.000132	0.000653	CcSEcCtD
Afatinib—Dermatitis—Felbamate—epilepsy syndrome	0.000132	0.000653	CcSEcCtD
Afatinib—ABCB1—cerebellum—epilepsy syndrome	0.000132	0.00186	CbGeAlD
Afatinib—Headache—Felbamate—epilepsy syndrome	0.000132	0.000649	CcSEcCtD
Afatinib—Dizziness—Clonazepam—epilepsy syndrome	0.000131	0.000647	CcSEcCtD
Afatinib—Nausea—Vigabatrin—epilepsy syndrome	0.000131	0.000646	CcSEcCtD
Afatinib—Vomiting—Zonisamide—epilepsy syndrome	0.000131	0.000645	CcSEcCtD
Afatinib—Insomnia—Valproic Acid—epilepsy syndrome	0.000131	0.000644	CcSEcCtD
Afatinib—Asthenia—Lamotrigine—epilepsy syndrome	0.00013	0.000643	CcSEcCtD
Afatinib—Dizziness—Phenytoin—epilepsy syndrome	0.00013	0.000642	CcSEcCtD
Afatinib—Rash—Zonisamide—epilepsy syndrome	0.00013	0.00064	CcSEcCtD
Afatinib—Infection—Pregabalin—epilepsy syndrome	0.00013	0.00064	CcSEcCtD
Afatinib—Dermatitis—Zonisamide—epilepsy syndrome	0.00013	0.000639	CcSEcCtD
Afatinib—Dizziness—Oxcarbazepine—epilepsy syndrome	0.00013	0.000639	CcSEcCtD
Afatinib—Nausea—Diazepam—epilepsy syndrome	0.000129	0.000636	CcSEcCtD
Afatinib—Headache—Zonisamide—epilepsy syndrome	0.000129	0.000636	CcSEcCtD
Afatinib—Dyspnoea—Valproic Acid—epilepsy syndrome	0.000129	0.000635	CcSEcCtD
Afatinib—Diarrhoea—Carbamazepine—epilepsy syndrome	0.000129	0.000634	CcSEcCtD
Afatinib—Pruritus—Lamotrigine—epilepsy syndrome	0.000129	0.000634	CcSEcCtD
Afatinib—Nervous system disorder—Pregabalin—epilepsy syndrome	0.000128	0.000631	CcSEcCtD
Afatinib—Cough—Gabapentin—epilepsy syndrome	0.000128	0.000631	CcSEcCtD
Afatinib—Mediastinal disorder—Topiramate—epilepsy syndrome	0.000128	0.00063	CcSEcCtD
Afatinib—Dyspepsia—Valproic Acid—epilepsy syndrome	0.000127	0.000627	CcSEcCtD
Afatinib—Skin disorder—Pregabalin—epilepsy syndrome	0.000127	0.000625	CcSEcCtD
Afatinib—Vomiting—Clonazepam—epilepsy syndrome	0.000126	0.000622	CcSEcCtD
Afatinib—Decreased appetite—Valproic Acid—epilepsy syndrome	0.000125	0.000619	CcSEcCtD
Afatinib—Alopecia—Topiramate—epilepsy syndrome	0.000125	0.000618	CcSEcCtD
Afatinib—Vomiting—Phenytoin—epilepsy syndrome	0.000125	0.000618	CcSEcCtD
Afatinib—Rash—Clonazepam—epilepsy syndrome	0.000125	0.000617	CcSEcCtD
Afatinib—Dermatitis—Clonazepam—epilepsy syndrome	0.000125	0.000616	CcSEcCtD
Afatinib—Nausea—Felbamate—epilepsy syndrome	0.000125	0.000616	CcSEcCtD
Afatinib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	0.000125	0.000615	CcSEcCtD
Afatinib—Vomiting—Oxcarbazepine—epilepsy syndrome	0.000125	0.000614	CcSEcCtD
Afatinib—Fatigue—Valproic Acid—epilepsy syndrome	0.000124	0.000614	CcSEcCtD
Afatinib—Dizziness—Carbamazepine—epilepsy syndrome	0.000124	0.000613	CcSEcCtD
Afatinib—Diarrhoea—Lamotrigine—epilepsy syndrome	0.000124	0.000613	CcSEcCtD
Afatinib—Headache—Clonazepam—epilepsy syndrome	0.000124	0.000613	CcSEcCtD
Afatinib—Rash—Phenytoin—epilepsy syndrome	0.000124	0.000612	CcSEcCtD
Afatinib—Mental disorder—Topiramate—epilepsy syndrome	0.000124	0.000612	CcSEcCtD
Afatinib—Dermatitis—Phenytoin—epilepsy syndrome	0.000124	0.000612	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	0.000124	0.000612	CcSEcCtD
Afatinib—Rash—Oxcarbazepine—epilepsy syndrome	0.000123	0.000609	CcSEcCtD
Afatinib—Constipation—Valproic Acid—epilepsy syndrome	0.000123	0.000609	CcSEcCtD
Afatinib—Dermatitis—Oxcarbazepine—epilepsy syndrome	0.000123	0.000609	CcSEcCtD
Afatinib—Headache—Phenytoin—epilepsy syndrome	0.000123	0.000608	CcSEcCtD
Afatinib—Malnutrition—Topiramate—epilepsy syndrome	0.000123	0.000608	CcSEcCtD
Afatinib—Headache—Oxcarbazepine—epilepsy syndrome	0.000123	0.000605	CcSEcCtD
Afatinib—Nausea—Zonisamide—epilepsy syndrome	0.000122	0.000603	CcSEcCtD
Afatinib—Dysgeusia—Topiramate—epilepsy syndrome	0.000121	0.000596	CcSEcCtD
Afatinib—Dizziness—Lamotrigine—epilepsy syndrome	0.00012	0.000593	CcSEcCtD
Afatinib—Vomiting—Carbamazepine—epilepsy syndrome	0.00012	0.000589	CcSEcCtD
Afatinib—Back pain—Topiramate—epilepsy syndrome	0.000119	0.000589	CcSEcCtD
Afatinib—Infection—Gabapentin—epilepsy syndrome	0.000119	0.000586	CcSEcCtD
Afatinib—Muscle spasms—Topiramate—epilepsy syndrome	0.000119	0.000585	CcSEcCtD
Afatinib—Rash—Carbamazepine—epilepsy syndrome	0.000119	0.000585	CcSEcCtD
Afatinib—Dermatitis—Carbamazepine—epilepsy syndrome	0.000118	0.000584	CcSEcCtD
Afatinib—Insomnia—Pregabalin—epilepsy syndrome	0.000118	0.000582	CcSEcCtD
Afatinib—Nausea—Clonazepam—epilepsy syndrome	0.000118	0.000581	CcSEcCtD
Afatinib—Headache—Carbamazepine—epilepsy syndrome	0.000118	0.000581	CcSEcCtD
Afatinib—Nervous system disorder—Gabapentin—epilepsy syndrome	0.000117	0.000579	CcSEcCtD
Afatinib—Nausea—Phenytoin—epilepsy syndrome	0.000117	0.000577	CcSEcCtD
Afatinib—Dyspnoea—Pregabalin—epilepsy syndrome	0.000116	0.000574	CcSEcCtD
Afatinib—Nausea—Oxcarbazepine—epilepsy syndrome	0.000116	0.000574	CcSEcCtD
Afatinib—Skin disorder—Gabapentin—epilepsy syndrome	0.000116	0.000573	CcSEcCtD
Afatinib—Vomiting—Lamotrigine—epilepsy syndrome	0.000115	0.00057	CcSEcCtD
Afatinib—Rash—Lamotrigine—epilepsy syndrome	0.000115	0.000565	CcSEcCtD
Afatinib—Dermatitis—Lamotrigine—epilepsy syndrome	0.000114	0.000564	CcSEcCtD
Afatinib—Body temperature increased—Valproic Acid—epilepsy syndrome	0.000114	0.000563	CcSEcCtD
Afatinib—Headache—Lamotrigine—epilepsy syndrome	0.000114	0.000561	CcSEcCtD
Afatinib—Decreased appetite—Pregabalin—epilepsy syndrome	0.000113	0.00056	CcSEcCtD
Afatinib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	0.000113	0.000556	CcSEcCtD
Afatinib—Fatigue—Pregabalin—epilepsy syndrome	0.000113	0.000555	CcSEcCtD
Afatinib—Nausea—Carbamazepine—epilepsy syndrome	0.000112	0.000551	CcSEcCtD
Afatinib—Constipation—Pregabalin—epilepsy syndrome	0.000112	0.00055	CcSEcCtD
Afatinib—Vandetanib—ALB—epilepsy syndrome	0.000108	0.0149	CrCbGaD
Afatinib—Insomnia—Gabapentin—epilepsy syndrome	0.000108	0.000534	CcSEcCtD
Afatinib—Nausea—Lamotrigine—epilepsy syndrome	0.000108	0.000532	CcSEcCtD
Afatinib—Cough—Topiramate—epilepsy syndrome	0.000108	0.000531	CcSEcCtD
Afatinib—ABCB1—brain—epilepsy syndrome	0.000107	0.00151	CbGeAlD
Afatinib—Dyspnoea—Gabapentin—epilepsy syndrome	0.000107	0.000526	CcSEcCtD
Afatinib—Dyspepsia—Gabapentin—epilepsy syndrome	0.000105	0.00052	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	0.000104	0.000514	CcSEcCtD
Afatinib—Decreased appetite—Gabapentin—epilepsy syndrome	0.000104	0.000513	CcSEcCtD
Afatinib—Asthenia—Valproic Acid—epilepsy syndrome	0.000104	0.000511	CcSEcCtD
Afatinib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	0.000103	0.00051	CcSEcCtD
Afatinib—Fatigue—Gabapentin—epilepsy syndrome	0.000103	0.000509	CcSEcCtD
Afatinib—Body temperature increased—Pregabalin—epilepsy syndrome	0.000103	0.000509	CcSEcCtD
Afatinib—Gefitinib—ALB—epilepsy syndrome	0.000103	0.0141	CrCbGaD
Afatinib—Constipation—Gabapentin—epilepsy syndrome	0.000102	0.000505	CcSEcCtD
Afatinib—Pruritus—Valproic Acid—epilepsy syndrome	0.000102	0.000504	CcSEcCtD
Afatinib—Infection—Topiramate—epilepsy syndrome	0.0001	0.000493	CcSEcCtD
Afatinib—Diarrhoea—Valproic Acid—epilepsy syndrome	9.88e-05	0.000487	CcSEcCtD
Afatinib—Nervous system disorder—Topiramate—epilepsy syndrome	9.87e-05	0.000487	CcSEcCtD
Afatinib—Gefitinib—ABCB1—epilepsy syndrome	9.83e-05	0.0135	CrCbGaD
Afatinib—Skin disorder—Topiramate—epilepsy syndrome	9.78e-05	0.000482	CcSEcCtD
Afatinib—Dizziness—Valproic Acid—epilepsy syndrome	9.55e-05	0.000471	CcSEcCtD
Afatinib—Body temperature increased—Gabapentin—epilepsy syndrome	9.46e-05	0.000467	CcSEcCtD
Afatinib—Asthenia—Pregabalin—epilepsy syndrome	9.36e-05	0.000462	CcSEcCtD
Afatinib—Pruritus—Pregabalin—epilepsy syndrome	9.23e-05	0.000455	CcSEcCtD
Afatinib—Vomiting—Valproic Acid—epilepsy syndrome	9.18e-05	0.000453	CcSEcCtD
Afatinib—Insomnia—Topiramate—epilepsy syndrome	9.11e-05	0.000449	CcSEcCtD
Afatinib—Rash—Valproic Acid—epilepsy syndrome	9.1e-05	0.000449	CcSEcCtD
Afatinib—Dermatitis—Valproic Acid—epilepsy syndrome	9.09e-05	0.000449	CcSEcCtD
Afatinib—Headache—Valproic Acid—epilepsy syndrome	9.04e-05	0.000446	CcSEcCtD
Afatinib—Dyspnoea—Topiramate—epilepsy syndrome	8.98e-05	0.000443	CcSEcCtD
Afatinib—Diarrhoea—Pregabalin—epilepsy syndrome	8.93e-05	0.00044	CcSEcCtD
Afatinib—Dyspepsia—Topiramate—epilepsy syndrome	8.86e-05	0.000437	CcSEcCtD
Afatinib—Decreased appetite—Topiramate—epilepsy syndrome	8.75e-05	0.000432	CcSEcCtD
Afatinib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	8.69e-05	0.000429	CcSEcCtD
Afatinib—Fatigue—Topiramate—epilepsy syndrome	8.68e-05	0.000428	CcSEcCtD
Afatinib—Dizziness—Pregabalin—epilepsy syndrome	8.63e-05	0.000426	CcSEcCtD
Afatinib—Constipation—Topiramate—epilepsy syndrome	8.61e-05	0.000425	CcSEcCtD
Afatinib—Asthenia—Gabapentin—epilepsy syndrome	8.59e-05	0.000424	CcSEcCtD
Afatinib—Nausea—Valproic Acid—epilepsy syndrome	8.57e-05	0.000423	CcSEcCtD
Afatinib—Pruritus—Gabapentin—epilepsy syndrome	8.47e-05	0.000418	CcSEcCtD
Afatinib—Vomiting—Pregabalin—epilepsy syndrome	8.3e-05	0.000409	CcSEcCtD
Afatinib—Rash—Pregabalin—epilepsy syndrome	8.23e-05	0.000406	CcSEcCtD
Afatinib—Dermatitis—Pregabalin—epilepsy syndrome	8.22e-05	0.000406	CcSEcCtD
Afatinib—Diarrhoea—Gabapentin—epilepsy syndrome	8.19e-05	0.000404	CcSEcCtD
Afatinib—Headache—Pregabalin—epilepsy syndrome	8.18e-05	0.000403	CcSEcCtD
Afatinib—Body temperature increased—Topiramate—epilepsy syndrome	7.96e-05	0.000393	CcSEcCtD
Afatinib—Dizziness—Gabapentin—epilepsy syndrome	7.91e-05	0.00039	CcSEcCtD
Afatinib—Nausea—Pregabalin—epilepsy syndrome	7.75e-05	0.000382	CcSEcCtD
Afatinib—Vomiting—Gabapentin—epilepsy syndrome	7.61e-05	0.000375	CcSEcCtD
Afatinib—Rash—Gabapentin—epilepsy syndrome	7.54e-05	0.000372	CcSEcCtD
Afatinib—Dermatitis—Gabapentin—epilepsy syndrome	7.54e-05	0.000372	CcSEcCtD
Afatinib—Headache—Gabapentin—epilepsy syndrome	7.5e-05	0.00037	CcSEcCtD
Afatinib—Asthenia—Topiramate—epilepsy syndrome	7.22e-05	0.000356	CcSEcCtD
Afatinib—Pruritus—Topiramate—epilepsy syndrome	7.12e-05	0.000351	CcSEcCtD
Afatinib—Nausea—Gabapentin—epilepsy syndrome	7.11e-05	0.000351	CcSEcCtD
Afatinib—Diarrhoea—Topiramate—epilepsy syndrome	6.89e-05	0.00034	CcSEcCtD
Afatinib—Dizziness—Topiramate—epilepsy syndrome	6.66e-05	0.000328	CcSEcCtD
Afatinib—Vomiting—Topiramate—epilepsy syndrome	6.4e-05	0.000316	CcSEcCtD
Afatinib—Rash—Topiramate—epilepsy syndrome	6.35e-05	0.000313	CcSEcCtD
Afatinib—Dermatitis—Topiramate—epilepsy syndrome	6.34e-05	0.000313	CcSEcCtD
Afatinib—Headache—Topiramate—epilepsy syndrome	6.31e-05	0.000311	CcSEcCtD
Afatinib—Nausea—Topiramate—epilepsy syndrome	5.98e-05	0.000295	CcSEcCtD
Afatinib—ERBB2—Disease—SRC—epilepsy syndrome	5.23e-06	2.73e-05	CbGpPWpGaD
Afatinib—LCK—Disease—FYN—epilepsy syndrome	5.22e-06	2.73e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—YWHAZ—epilepsy syndrome	5.21e-06	2.72e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—RELA—epilepsy syndrome	5.21e-06	2.72e-05	CbGpPWpGaD
Afatinib—LCK—Disease—H2AFX—epilepsy syndrome	5.2e-06	2.72e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—DUSP6—epilepsy syndrome	5.2e-06	2.71e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—epilepsy syndrome	5.2e-06	2.71e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—VEGFA—epilepsy syndrome	5.18e-06	2.7e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—SRC—epilepsy syndrome	5.15e-06	2.69e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADRA2A—epilepsy syndrome	5.13e-06	2.68e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HTR2A—epilepsy syndrome	5.13e-06	2.68e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL12—epilepsy syndrome	5.12e-06	2.67e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BDKRB2—epilepsy syndrome	5.12e-06	2.67e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—AKT1—epilepsy syndrome	5.12e-06	2.67e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PLAT—epilepsy syndrome	5.11e-06	2.67e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MTOR—epilepsy syndrome	5.11e-06	2.66e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PRKCB—epilepsy syndrome	5.1e-06	2.66e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6ST—epilepsy syndrome	5.08e-06	2.65e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—JUN—epilepsy syndrome	5.05e-06	2.63e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—TSC2—epilepsy syndrome	5.04e-06	2.63e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CRP—epilepsy syndrome	5.04e-06	2.63e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—SRC—epilepsy syndrome	5.03e-06	2.62e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JUNB—epilepsy syndrome	5.02e-06	2.62e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CNR1—epilepsy syndrome	5.02e-06	2.62e-05	CbGpPWpGaD
Afatinib—LCK—Disease—YWHAZ—epilepsy syndrome	5.02e-06	2.62e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—FGF2—epilepsy syndrome	5.02e-06	2.62e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CCR5—epilepsy syndrome	5.01e-06	2.61e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PLCB1—epilepsy syndrome	5.01e-06	2.61e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—FOS—epilepsy syndrome	4.97e-06	2.59e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—FGF2—epilepsy syndrome	4.94e-06	2.58e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL12—epilepsy syndrome	4.93e-06	2.57e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BDKRB2—epilepsy syndrome	4.93e-06	2.57e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—AKT1—epilepsy syndrome	4.93e-06	2.57e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HTR7—epilepsy syndrome	4.9e-06	2.56e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—VEGFA—epilepsy syndrome	4.9e-06	2.56e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TSC2—epilepsy syndrome	4.88e-06	2.55e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AGT—epilepsy syndrome	4.87e-06	2.54e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—TSC2—epilepsy syndrome	4.86e-06	2.54e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CRP—epilepsy syndrome	4.86e-06	2.54e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CASP8—epilepsy syndrome	4.86e-06	2.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JUNB—epilepsy syndrome	4.84e-06	2.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CNR1—epilepsy syndrome	4.84e-06	2.53e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CCR5—epilepsy syndrome	4.83e-06	2.52e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PLCB1—epilepsy syndrome	4.82e-06	2.52e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—epilepsy syndrome	4.79e-06	2.5e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—APOE—epilepsy syndrome	4.77e-06	2.49e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HBEGF—epilepsy syndrome	4.76e-06	2.48e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—KCNJ11—epilepsy syndrome	4.74e-06	2.47e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CHRM3—epilepsy syndrome	4.74e-06	2.47e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HTR7—epilepsy syndrome	4.72e-06	2.47e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1B—epilepsy syndrome	4.71e-06	2.46e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—SRC—epilepsy syndrome	4.7e-06	2.45e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KDR—epilepsy syndrome	4.68e-06	2.44e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT3—epilepsy syndrome	4.67e-06	2.44e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TSC2—epilepsy syndrome	4.66e-06	2.43e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—RELA—epilepsy syndrome	4.66e-06	2.43e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PRKCB—epilepsy syndrome	4.66e-06	2.43e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—HMOX1—epilepsy syndrome	4.65e-06	2.43e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—POMC—epilepsy syndrome	4.64e-06	2.42e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6ST—epilepsy syndrome	4.64e-06	2.42e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CAT—epilepsy syndrome	4.59e-06	2.39e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—RELA—epilepsy syndrome	4.59e-06	2.39e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HBEGF—epilepsy syndrome	4.59e-06	2.39e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MTOR—epilepsy syndrome	4.57e-06	2.38e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ADAM10—epilepsy syndrome	4.56e-06	2.38e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—JUN—epilepsy syndrome	4.56e-06	2.38e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—APOE—epilepsy syndrome	4.56e-06	2.38e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCL2—epilepsy syndrome	4.54e-06	2.37e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—SRC—epilepsy syndrome	4.53e-06	2.36e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—SRC—epilepsy syndrome	4.51e-06	2.35e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT3—epilepsy syndrome	4.5e-06	2.35e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PRKCB—epilepsy syndrome	4.5e-06	2.35e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MTOR—epilepsy syndrome	4.5e-06	2.35e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TSC2—epilepsy syndrome	4.49e-06	2.34e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PRKCB—epilepsy syndrome	4.49e-06	2.34e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6ST—epilepsy syndrome	4.48e-06	2.34e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6ST—epilepsy syndrome	4.47e-06	2.33e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ABCB1—epilepsy syndrome	4.46e-06	2.33e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—epilepsy syndrome	4.44e-06	2.32e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADAM10—epilepsy syndrome	4.4e-06	2.29e-05	CbGpPWpGaD
Afatinib—LCK—Disease—APOE—epilepsy syndrome	4.39e-06	2.29e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—FGF2—epilepsy syndrome	4.39e-06	2.29e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—AKT1—epilepsy syndrome	4.37e-06	2.28e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—SRC—epilepsy syndrome	4.35e-06	2.27e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—S100B—epilepsy syndrome	4.31e-06	2.25e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6ST—epilepsy syndrome	4.28e-06	2.23e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SOCS3—epilepsy syndrome	4.27e-06	2.23e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDC42—epilepsy syndrome	4.26e-06	2.22e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—FOS—epilepsy syndrome	4.25e-06	2.22e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS2—epilepsy syndrome	4.25e-06	2.22e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CASP3—epilepsy syndrome	4.2e-06	2.19e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—BCL2—epilepsy syndrome	4.17e-06	2.17e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—S100B—epilepsy syndrome	4.16e-06	2.17e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CASP8—epilepsy syndrome	4.15e-06	2.17e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GPX1—epilepsy syndrome	4.15e-06	2.16e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CASP3—epilepsy syndrome	4.14e-06	2.16e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AVP—epilepsy syndrome	4.13e-06	2.15e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6ST—epilepsy syndrome	4.13e-06	2.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SOCS3—epilepsy syndrome	4.12e-06	2.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDC42—epilepsy syndrome	4.11e-06	2.14e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—POMC—epilepsy syndrome	4.1e-06	2.14e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—FOS—epilepsy syndrome	4.09e-06	2.14e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS2—epilepsy syndrome	4.09e-06	2.14e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—SRC—epilepsy syndrome	4.09e-06	2.14e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—JUN—epilepsy syndrome	4.08e-06	2.13e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—RELA—epilepsy syndrome	4.07e-06	2.13e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—JUN—epilepsy syndrome	4.02e-06	2.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCL2—epilepsy syndrome	4.01e-06	2.09e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CASP8—epilepsy syndrome	4e-06	2.09e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MTOR—epilepsy syndrome	4e-06	2.09e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AVP—epilepsy syndrome	3.98e-06	2.08e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—epilepsy syndrome	3.97e-06	2.07e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—epilepsy syndrome	3.91e-06	2.04e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HES1—epilepsy syndrome	3.9e-06	2.04e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—AKT1—epilepsy syndrome	3.87e-06	2.02e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ABCG2—epilepsy syndrome	3.87e-06	2.02e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—AKT1—epilepsy syndrome	3.79e-06	1.98e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FYN—epilepsy syndrome	3.79e-06	1.98e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—H2AFX—epilepsy syndrome	3.78e-06	1.97e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MEF2C—epilepsy syndrome	3.77e-06	1.97e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2C19—epilepsy syndrome	3.77e-06	1.97e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HES1—epilepsy syndrome	3.76e-06	1.96e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—FGF2—epilepsy syndrome	3.75e-06	1.96e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP11A1—epilepsy syndrome	3.74e-06	1.95e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—epilepsy syndrome	3.68e-06	1.92e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—SRC—epilepsy syndrome	3.66e-06	1.91e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FYN—epilepsy syndrome	3.66e-06	1.91e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—YWHAZ—epilepsy syndrome	3.65e-06	1.9e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—H2AFX—epilepsy syndrome	3.64e-06	1.9e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AGT—epilepsy syndrome	3.64e-06	1.9e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MEF2C—epilepsy syndrome	3.64e-06	1.9e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FGF2—epilepsy syndrome	3.63e-06	1.89e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—FGF2—epilepsy syndrome	3.61e-06	1.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NGF—epilepsy syndrome	3.61e-06	1.88e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—SRC—epilepsy syndrome	3.6e-06	1.88e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—JUN—epilepsy syndrome	3.57e-06	1.86e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	3.57e-06	1.86e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOE—epilepsy syndrome	3.56e-06	1.86e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—epilepsy syndrome	3.56e-06	1.86e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—BCL2—epilepsy syndrome	3.56e-06	1.86e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—epilepsy syndrome	3.52e-06	1.84e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—YWHAZ—epilepsy syndrome	3.52e-06	1.83e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—epilepsy syndrome	3.51e-06	1.83e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCR5—epilepsy syndrome	3.51e-06	1.83e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—RELA—epilepsy syndrome	3.48e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NGF—epilepsy syndrome	3.48e-06	1.81e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—epilepsy syndrome	3.46e-06	1.81e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—FGF2—epilepsy syndrome	3.46e-06	1.81e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HTR2A—epilepsy syndrome	3.43e-06	1.79e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—BCL2—epilepsy syndrome	3.43e-06	1.79e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—epilepsy syndrome	3.42e-06	1.78e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MTOR—epilepsy syndrome	3.41e-06	1.78e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCR5—epilepsy syndrome	3.38e-06	1.76e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	3.38e-06	1.76e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RELA—epilepsy syndrome	3.37e-06	1.76e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—RELA—epilepsy syndrome	3.36e-06	1.75e-05	CbGpPWpGaD
Afatinib—LCK—Disease—FGF2—epilepsy syndrome	3.34e-06	1.74e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—epilepsy syndrome	3.33e-06	1.74e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HTR2A—epilepsy syndrome	3.31e-06	1.73e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—epilepsy syndrome	3.31e-06	1.72e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MTOR—epilepsy syndrome	3.3e-06	1.72e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MTOR—epilepsy syndrome	3.29e-06	1.72e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TSC2—epilepsy syndrome	3.26e-06	1.7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AGT—epilepsy syndrome	3.26e-06	1.7e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—epilepsy syndrome	3.25e-06	1.69e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	3.22e-06	1.68e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	3.22e-06	1.68e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—BCHE—epilepsy syndrome	3.2e-06	1.67e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—SRC—epilepsy syndrome	3.2e-06	1.67e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—epilepsy syndrome	3.2e-06	1.67e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOE—epilepsy syndrome	3.19e-06	1.67e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MTOR—epilepsy syndrome	3.15e-06	1.65e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—epilepsy syndrome	3.15e-06	1.64e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TSC2—epilepsy syndrome	3.14e-06	1.64e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AGT—epilepsy syndrome	3.14e-06	1.64e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KDR—epilepsy syndrome	3.13e-06	1.63e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—epilepsy syndrome	3.12e-06	1.63e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—epilepsy syndrome	3.12e-06	1.63e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOE—epilepsy syndrome	3.08e-06	1.61e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—POMC—epilepsy syndrome	3.06e-06	1.6e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	3.06e-06	1.59e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—JUN—epilepsy syndrome	3.05e-06	1.59e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MTOR—epilepsy syndrome	3.04e-06	1.59e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—epilepsy syndrome	3.04e-06	1.58e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—epilepsy syndrome	3.03e-06	1.58e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PLCB1—epilepsy syndrome	3.02e-06	1.58e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KDR—epilepsy syndrome	3.01e-06	1.57e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TH—epilepsy syndrome	3.01e-06	1.57e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PRKCB—epilepsy syndrome	3.01e-06	1.57e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—epilepsy syndrome	3.01e-06	1.57e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6ST—epilepsy syndrome	3e-06	1.56e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JUN—epilepsy syndrome	2.95e-06	1.54e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—JUN—epilepsy syndrome	2.94e-06	1.53e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—epilepsy syndrome	2.92e-06	1.52e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PRKCB—epilepsy syndrome	2.9e-06	1.51e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6ST—epilepsy syndrome	2.89e-06	1.51e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—epilepsy syndrome	2.87e-06	1.5e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—epilepsy syndrome	2.81e-06	1.47e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—epilepsy syndrome	2.8e-06	1.46e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—epilepsy syndrome	2.79e-06	1.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—POMC—epilepsy syndrome	2.74e-06	1.43e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—SRC—epilepsy syndrome	2.74e-06	1.43e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—epilepsy syndrome	2.7e-06	1.41e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL2—epilepsy syndrome	2.68e-06	1.4e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SRC—epilepsy syndrome	2.65e-06	1.38e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—POMC—epilepsy syndrome	2.64e-06	1.38e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—SRC—epilepsy syndrome	2.64e-06	1.38e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL2—epilepsy syndrome	2.59e-06	1.35e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—epilepsy syndrome	2.58e-06	1.34e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—epilepsy syndrome	2.54e-06	1.33e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SRC—epilepsy syndrome	2.53e-06	1.32e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMOX1—epilepsy syndrome	2.51e-06	1.31e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAT—epilepsy syndrome	2.48e-06	1.29e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	2.44e-06	1.27e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SRC—epilepsy syndrome	2.43e-06	1.27e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGF2—epilepsy syndrome	2.42e-06	1.27e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGF2—epilepsy syndrome	2.34e-06	1.22e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—epilepsy syndrome	2.27e-06	1.19e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RELA—epilepsy syndrome	2.25e-06	1.17e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GPX1—epilepsy syndrome	2.24e-06	1.17e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—epilepsy syndrome	2.24e-06	1.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MTOR—epilepsy syndrome	2.21e-06	1.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RELA—epilepsy syndrome	2.17e-06	1.13e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MTOR—epilepsy syndrome	2.13e-06	1.11e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—epilepsy syndrome	2.03e-06	1.06e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—epilepsy syndrome	1.99e-06	1.04e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JUN—epilepsy syndrome	1.97e-06	1.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AGT—epilepsy syndrome	1.97e-06	1.03e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—epilepsy syndrome	1.96e-06	1.02e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOE—epilepsy syndrome	1.93e-06	1.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—epilepsy syndrome	1.92e-06	1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JUN—epilepsy syndrome	1.9e-06	9.92e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—epilepsy syndrome	1.86e-06	9.71e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—epilepsy syndrome	1.85e-06	9.65e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SRC—epilepsy syndrome	1.77e-06	9.23e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—epilepsy syndrome	1.72e-06	8.99e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SRC—epilepsy syndrome	1.7e-06	8.9e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—epilepsy syndrome	1.7e-06	8.87e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—epilepsy syndrome	1.66e-06	8.66e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—POMC—epilepsy syndrome	1.66e-06	8.64e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—epilepsy syndrome	1.64e-06	8.58e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—epilepsy syndrome	1.64e-06	8.55e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—epilepsy syndrome	1.57e-06	8.19e-06	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—epilepsy syndrome	1.51e-06	7.89e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—epilepsy syndrome	1.51e-06	7.88e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—epilepsy syndrome	1.32e-06	6.89e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—epilepsy syndrome	1.23e-06	6.4e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—epilepsy syndrome	1.1e-06	5.74e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—epilepsy syndrome	1.06e-06	5.53e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—epilepsy syndrome	6.64e-07	3.46e-06	CbGpPWpGaD
